NCT07359287 Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
| NCT ID | NCT07359287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Angina |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,500 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,500 participants in total. It began in 2025-12-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common. We are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines. The study will include six primary care practices (24 physicians), with three practices in each study arm. The aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a "viral infection prescription" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.
Eligibility Criteria
Inclusion Criteria: \- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, COPD exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis / Nasopharyngitis, Acute sinusitis) Exclusion Criteria: \- Patient under legal protection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07359287 clinical trial?
This trial is open to participants of all sexes, studying Angina. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07359287 currently recruiting?
Yes, NCT07359287 is actively recruiting participants. Contact the research team at verdon-r@chu-caen.fr for enrollment information.
Where is the NCT07359287 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT07359287 clinical trial?
NCT07359287 is sponsored by University Hospital, Caen. The trial plans to enroll 4,500 participants.